These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2093184)
41. Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions. Darmani NA; Martin BR; Pandey U; Glennon RA Pharmacol Biochem Behav; 1990 Sep; 37(1):95-9. PubMed ID: 2263671 [TBL] [Abstract][Full Text] [Related]
42. Dose- and time-dependent effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism in awake rats. Freo U; Soncrant TT; Holloway HW; Rapoport SI Brain Res; 1991 Feb; 541(1):63-9. PubMed ID: 2029625 [TBL] [Abstract][Full Text] [Related]
43. Effect of the 5-HT receptor agonist DOI on female rat sexual behavior. Rössler AS; Bernabé J; Denys P; Alexandre L; Giuliano F J Sex Med; 2006 May; 3(3):432-41. PubMed ID: 16681468 [TBL] [Abstract][Full Text] [Related]
44. Effects of repeated treatment with 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on the autoregulatory control of dorsal raphe 5-HT neuronal firing and cortical 5-HT release. Kidd EJ; Garratt JC; Marsden CA Eur J Pharmacol; 1991 Jul; 200(1):131-9. PubMed ID: 1837523 [TBL] [Abstract][Full Text] [Related]
45. Prevention of DOI-mediated wet dog shakes by inhibitors of nitric oxide synthase. Xu X; Miller KJ Brain Res; 1998 Sep; 804(2):337-40. PubMed ID: 9757078 [TBL] [Abstract][Full Text] [Related]
46. Behavioural and biochemical evidence that glucocorticoids are not involved in DOI-elicited 5-HT2 receptor down-regulation. Chaouloff F; Baudrie V; Coupry I Eur J Pharmacol; 1993 Nov; 249(1):117-20. PubMed ID: 8282013 [TBL] [Abstract][Full Text] [Related]
47. Effects of chronic administration of haloperidol, methamphetamine or cocaine on "wet-dog shakes" elicited by stimulation of the rat hippocampus. Araki H; Uchiyama-Tsuyuki Y; Aihara H; Yamamoto T; Ohno M; Ueki S Arch Int Pharmacodyn Ther; 1989; 297():217-24. PubMed ID: 2730237 [TBL] [Abstract][Full Text] [Related]
49. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat. Baudrie V; De Vry J; Broqua P; Schmidt B; Chaouloff F; Glaser T Eur J Pharmacol; 1993 Feb; 231(3):395-406. PubMed ID: 8095465 [TBL] [Abstract][Full Text] [Related]
50. Behavioral characterization of non-copulating male rats with high spontaneous yawning frequency rate. Portillo W; Camacho F; Eguibar JR; Paredes RG Behav Brain Res; 2010 Dec; 214(2):225-30. PubMed ID: 20510299 [TBL] [Abstract][Full Text] [Related]
51. Repeated adolescent MDMA ("Ecstasy") exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist. Biezonski DK; Courtemanche AB; Hong SB; Piper BJ; Meyer JS Brain Res; 2009 Feb; 1252():87-93. PubMed ID: 19059385 [TBL] [Abstract][Full Text] [Related]
52. Characterization of DOI, a putative 5-HT2 receptor agonist in the rat. Dabiré H; Chaouche-Teyara K; Cherqui C; Fournier B; Laubie M; Schmitt H Eur J Pharmacol; 1989 Sep; 168(3):369-74. PubMed ID: 2583242 [TBL] [Abstract][Full Text] [Related]
53. Preclinical studies on LY237733, a potent and selective serotonergic antagonist. Foreman MM; Fuller RW; Nelson DL; Calligaro DO; Kurz KD; Misner JW; Garbrecht WL; Parli CJ J Pharmacol Exp Ther; 1992 Jan; 260(1):51-7. PubMed ID: 1731051 [TBL] [Abstract][Full Text] [Related]
54. Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI). Pranzatelli MR Neurosci Lett; 1990 Jul; 115(1):74-80. PubMed ID: 2216059 [TBL] [Abstract][Full Text] [Related]
55. Lack of effects of 5-HT3 antagonists on normal and morphine-attenuated sexual behaviours in female and male rats. Tanco SA; Watson NV; Gorzalka BB Experientia; 1993 Mar; 49(3):238-41. PubMed ID: 8458409 [TBL] [Abstract][Full Text] [Related]
56. Flibanserin treatment increases appetitive sexual motivation in the female rat. Gelez H; Greggain-Mohr J; Pfaus JG; Allers KA; Giuliano F J Sex Med; 2013 May; 10(5):1231-9. PubMed ID: 23421417 [TBL] [Abstract][Full Text] [Related]
57. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. Kleven MS; Assié MB; Koek W J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338 [TBL] [Abstract][Full Text] [Related]
58. Long-term sequential determination of behavioral ontogeny of 5-HT1A and 5-HT2 receptor functions in the rat. Darmani NA; Ahmad B J Pharmacol Exp Ther; 1999 Jan; 288(1):247-53. PubMed ID: 9862777 [TBL] [Abstract][Full Text] [Related]
59. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats. Zaniewska M; McCreary AC; Przegaliński E; Filip M Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403 [TBL] [Abstract][Full Text] [Related]
60. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Leysen JE; Janssen PF; Niemegeers CJ Eur J Pharmacol; 1989 Apr; 163(1):145-9. PubMed ID: 2545460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]